Amyloidosis trials in Austria

In Austria 10 Also abroad 184

10 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Innsbruck, St. Poelten, Vienna
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
No phaseNot yet taking people in Austria
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor
Where
Innsbruck
Age
18 years and over
People
60 worldwide
Run by
Bayer
See details and how to joinNCT07557147
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Vienna
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Braunau Am Inn, Graz, Vienna, Wels
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
Edge-to-edge Mitral Valve Repair in ATTR-CM
Where
Graz, Linz, Sankt Pölten, Vienna
Age
18 years and over
People
106 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06075823
Phase 4Taking people
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Where
Braunau am Inn, Feldkirch, Sankt Pölten, Vienna
Age
18 years to 90 years
People
50 worldwide
Run by
Bayer
See details and how to joinNCT07298044 · EU 2025-521831-35-00
No phaseTaking people
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Where
Multiple Locations
Age
18 years and over
People
2,000 worldwide
Run by
Bayer
See details and how to joinNCT07235462
Phase 3Not yet taking people in Austria
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Graz, Innsbruck, Vienna, Wels
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Graz, Innsbruck, Vienna
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
No phaseTaking people
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.
Where
Graz, Vienna
Age
18 years and over
People
600 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06836011